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Summary: Anti-pre-S antibody was tested in 38 sera from patients with fulminant hepatitis (positive for 
HBsAg and/or IgM anti-HBc) using a specific solid phase enzyme linked immunosorbent assay (ELISA). 
Anti-pre-S activity was detected in 50 percent sera samples positive for HBsAg but negative for IgM anti- 
HBc. There were 12.5% sera positive for both HBsAg as well as IgM anti-HBc and 75% sera negative for 
HBsAg but positive for IgM anti-HBc. The prevalence ofHBV-specific DNA-polymerase activity was high 
in all the three groups whereas anti-HBs positivity was low. Anti-pre-S activity was observed both in the 
presence as well as in the absence of DNA-polymerase activity. High-anti-pre-S level in fulminant hepatitis B
patients was assumed to be implicated in the fast clearance of HBsAg from circulation. Gastroenterol Jpn 
1990;25:499-502 
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Introduction 
Fulminant hepatic failure due to viral infection is 
an uncommon but severe complication of acute 
viral hepatitis 1.The reason why acute infection in 
some patients pursues a fulminant course is not 
yet known. Occurrence of massive hepatic ne- 
crosis in patients with fulminant hepatitis B has 
been attributed to an enhanced immune response 
against he HBV antigens 2. Both cell-mediated 
immunity as well as humoral immunity have been 
reported to be involved in the pathogenesis of
liver 3. There are several reports 2"3 demonstrating 
high anti-HBs and anti-HBe levels in sera from 
patients with fulminant hepatitis B. However, 
little information is available on the presence and 
significance of antibodies directed against pre-S 
proteins (anti-pre-S anti-bodies) in these patients. 
The present study, therefore, was carried out to 
detect anti-pre-S antibodies in the sera samples 
from patients with fulminant hepatitis (positive 
for IgM anti-HBc and/or HBsAg) by using a 
specific ELISA technique 4. Attempts were also 
made to establish a relation between prevalence 
of anti-pre-S antibody and HBV-replication dur- 
ing the course of the disease. 
Patients and Methods 
Patients 
A total of 38 patients of fulminant hepatitis, 
including 28 cases with viral hepatitis B (IgM anti- 
HBc positive) and 10 cases of non-B hepatitis 
(IgM anti-HBc negative but HBsAg positive) 
were admitted to the Rajgarhia Liver Unit of our 
institute in 1986 and 1987. All patients developed 
hepatic encephalopathy within 10 days of the 
onset of symptoms and signs of acute hepatitis in 
the absence of any pre-existing liver diseases. The 
sera from these patients were collected within one 
week of the onset of encephalopathy and kept at 
-70~ until used for anti pre-S analysis. 
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Table 1 Hepatitis B markers in patients with fulminant hepatitis 
Group No. Anti-HBs + Anti-pre-S § DNA-P § 
(a) HBsAg § and IgM anti-HBc- 10 1 (10%) 5 (50%) 3 (30%) 
(b) HBsAg § and IgM anti-HBc + 8 0 (Nil) 1 (12.5%) 4 (50%) 
(c) HBsAg- and IgM anti-HBc § 20 3 (15%) 15 (75%) 3 (35%) 
DNA-P: HBV-specific DNA-polymerase 
Serological nalysis 
HBsAg and anti-HBs in sera samples were 
tested as described in a previous report 5. IgM 
anti-HBc was tested by commercial EIA-kit ob- 
tained from Abbott Laboratories, Chicago, USA. 
HBV-specific DNA-polymerase activity was 
measured by the modified method of fang et al 6. 
ELISA-procedure 
The ELISA presently used for the detection of 
anti-pre-S antibody in serum is the same as de- 
scribed in a previous report 4. The test is a specific 
assay system and is based on competitive binding 
between anti-pre-S and horse radish peroxidase- 
labelled polymerised human serum albumin 
(HRPO-pHSA) for the pHSA-receptor site on 
HBsAg molecules fixed to a solid surface. Pre- 
treatment of HBsAg with anti-pre-S positive 
serum inhibits the subsequent binding of HRPO- 
pHSA conjugate to HBsAg. Percent inhibition of 
OD was used as the measurement of anti-pre-S 
activity in serum. The preparation of pHSA and 
its labelling with HRPO was carried out as de- 
scribed previously 5. In the ELISA procedure the 
antigen (HBsAg enriched in pHSA-receptor) was 
coated by addition of 50ul of HBsAg solution (1 
ng/ml) in carbonate buffer, pH9.6 to each well of 
a microtitre plate (Nunc, Denmark). The plate 
was incubated overnight (18-20 hrs) at room tem- 
perature followed by washings with 0.1 M phos- 
phate buffered saline, pH7.2 containing 0.05% 
Tween-20 (PBS-T), Postcoating was done by the 
addition of 200ul of 0.5% gelatin in PBS to each 
well. After washing, 50ul serum sampels were 
placed in each well and the plate was incubated at 
37~ for 2 hrs. Anti-HBs, if present in the test 
serum, was neutralized as described by Okamoto 
et al 7 before the addition of serum to the plate. 
The plate was washed 3 times and 50ul of opti- 
Table 2 Relation between anti-pre-S antibodies and HBV-DNA- 
polymerase in fulminant hepatitis patients 
DNA-P positivity in 
Group 
Anti-pre-S + Anti-pre-S-sera 
(a) HBsAg + and IgM anti-HBc 1/5 (20%) 2/5 (40%) 
(b) HBsAg § and IgM anti-HBc § 0/1 (Nil) 4/7 (57%) 
(c) HBsAg- and IgM anti-HBc + 5/15 (33%) 2/5 (40%) 
mally diluted HRPO-pHSA conjugate, (after 
proper dilution with PBS), was added to each well 
and incubated at 37~ for 2 hrs. After washing, 
color was developed by adding 50 ul of O-phenyl- 
ene-diamine solution (0.4 mg/ml) in 0.1M phos- 
phate citrate buffer, pH5.0 containing 0.06% 
H202 to each well. The reaction was stopped after 
15 rain by adding 50 ul of 4N H2SO 4 and the 
optical density was measured at 492 nm. The 
results were expressed in terms of percent inhibi- 
tion of O.D. i .e . :  
(O.D. of control) - (O.D. of sample) • 100 
(O.D. of control) 
Sera from healthy persons without HBV- 
markers erved as control. Any test serum causing 
more than 50% inhibition was considered positive 
for anti-pre-S activity. 
Results 
A total of 38 sera samples from the patients with 
fulminant hepatitis, belonging to three different 
groups (Table 1) was analyzed for anti-pre-S anti- 
body, anti-HBs and HBV-specific DNA-poly- 
merase activity. Anti-pre-S antibody was de- 
tected in 5 of 10 sera samples positive for HBsAg 
but negative for IgM anti-HBc, 1 of 8 sera smaples 
positive for both HBsAg as well as IgM anti-HBc 
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and 15 of 20 sera samples negative for HBsAg but 
positive for IgM anti-HBc. The prevalence of 
anti-HBs in these patients was very low. HBV- 
specific DNA-polymerase was present in a signifi- 
cant proportion in each group of patients. A study 
of the relationship between anti-pre-S positivity 
and DNA-polymerase activity revealed that 
DNA-polymerase was present both in the pre- 
sence as well as inthe absence of anti-pre-S activ- 
ity without any significant difference (Table 2). 
Discuss ion  
The pathogenesis of massive hepatic necrosis in 
fulminant hepatitis B remains enigmatic and 
seems more related to brisk host immune re- 
sponse than to direct cytopathogenicity or in- 
creased replication of hepatitis B virus. There is 
evidence of high anti-HBs and anti-HBe levels 3in 
serum samples of fulminant hepatitis B patients. 
It is assumed that these antibodies complexed 
with antigens cause an Arthus reaction in hepatic 
sinusoids leading to ischemic necrosis of the hepa- 
tocytes. The enhanced immune response is also 
reported to cease HBV-replication after hepatic 
encephalopathy I. However, there is no report 
available which show the status and the possible 
role of anti-pre-S antibodies infulminant hepatitis 
patients with evidence of present or past HBV 
infection. 
In the present study, anti-pre-S activity was 
evaluated by the ELISA method, the specificity of 
which has already been established in a previous 
paper 4. The present series of 38 patients with 
fulminant hepatitis (positive for either IgM anti- 
HBc and/or HBsAg) demonstrated a low preva- 
lence of anti-HBs but moderately high prevalence 
of HBV-specific DNA-polymerase. These find- 
ings are different from the previous reports 2'3 
showing high anti-HBs positivity and low HBV- 
replication in fulminant hepatitis. A significantly 
high proportion of sera showed anti-pre-S anti- 
body activity. In non-fulminant hepatitis B, i.e. 
acute viral hepatitis B cases, anti-pre-S activity 
was recorded in only one of 24 (4.2%) cases as 
published in our previous paper 4. Thus anti-pre-S 
in fulminant hepatitis i  significantly high as com-  
pared to non fulminant hepatitis. High prevalence 
of anti-pre-S activity in fulminant patients has also 
been reported by Thielmann et al s, though the 
number of sera analyzed was very small i.e. only 
3. These findings indicate that fulminant patients 
show a brisk immune response to pre-S protein 
resulting in an early appearance ofanti-pre-S anti- 
bodies, i.e. even before the disappearance of pre- 
S proteins or HBV-replications. The appearance 
of anti-pre-S in the presence of pre-S proteins and 
HBV-DNA has been demonstrated in experi- 
mentally infected chimpanzees as well as in pa- 
tients with acute HBV-infection s. The low anti- 
HBs positivity in fulminant patients indicate that 
a brisk immune response ispresent exclusively to 
pre-S proteins and not to HBsAg. This is sup- 
ported by the findings of Milich et al 9 suggesting 
that immune responses against pre-S proteins and 
HBsAg are regulated independently. 
Based on HBsAg and IgM anti-HBc status in 
sera, the patients with fulminant hepatitis were 
divided into 3 different groups. The presence of 
anti-pre-S antibody in group (a) patients, which 
represent either a non-B infection in HBsAg 
carriers or an early stage of HBV-infection, indi- 
cates an early appearanceof anti-pre-S, i.e. before 
the development of IgM anti-HBc. Presumably, 
this is the IgM type of anti-pre-S antibody. Since 
anti-pre-S appears in a biphasic pattern 7 the low 
level of anti-pre-S in group (b) patients which 
represent the middle and peak stage of disease, 
may correspond to the declining phase before it 
reappears again. In group (c) patients, represent- 
ing a late stage of the disease, anti-pre-S appeared 
in the second phase and thus represents he IgG 
type of anti-pre-S as reported earlier s. Absence of 
HBsAg in group (c) patients may be ascribed to 
the neutralizing effectof anti-pre-S present in high 
level. Fast clearance of HBsAg in fulminant hepa- 
titis B patients has been reported earlier 1and it 
was attributed to an enhanced immune response 
resulting in either cessation of HBV-replication 
or the masking of HBsAg synthesis by massive 
anti-HBs production. Since in the present cases, 
anti-HBs positivity is very low and at the same 
time anti-pre-S is reported to be involved in the 
clearance of HBsAg 1~ high anti-pre-S level in 
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group (c) patients possibly clears off HBsAg by 
neutralization. However, anti-pre-S does not ar- 
rest HBV-replication, as is evident by high DNA- 
polymerase activity, suggesting that anti-pre-S 
clears off only the released HBsAg from hepato- 
cyters without interfering in HBV-replication. 
The clearance of HBsAg by anti-pre-S predomi- 
nates over its production. 
Anti-pre-S antibody in fulminant patients 
seems to play a major role of clearing HBsAg 
from circulation. Its function is different form that 
of anti-HBs which possibly is involved more in the 
pathogenesis than the clearance of HBsAg. Anti- 
pre-S helps in clearing HBsAg by neutralizing it. 
The present study does not explain the massive 
liver necrosis in fulminant patients, particularly 
when anti-HBs positivity is so low. Possibly, 
factors other than high anti-HBs level are also 
responsible for the liver damage. 
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